Showing 1 - 2 results of 2 for search 'Bluemmert, I', query time: 1.04s
Refine Results
-
1
Outcomes for patients with late-stage mutant-IDH2 (m IDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the ra... by DiNardo, CD, Montesinos, P, Schuh, AC, Papayannidis, C, Vyas, P, Wei, AH, Zeidan, AM, Bluemmert, I, Yu, X, Hasan, M, Martin-Regueira, P, de Botton, S
Published 2021Conference item -
2
AML-432 Overall survival (OS) by IDH2 mutant allele (R140 or R172) in patients with late-stage, mutant-IDH2 relapsed/refractory acute myeloid leukemia (AML) treated with enasidenib... by DiNardo, CD, de Botton, S, Risueño, A, Schuh, AC, Löwenberg, B, Kim, HJ, Vyas, P, Wei, AH, Stein, EM, Döhner, H, Fathi, AT, Martin-Regueira, P, Taningco, L, Bluemmert, I, Yu, X, See, WL, Hasan, M
Published 2022Conference item